MarketResearchReports.com: Rheumatoid Arthritis - Pipeline Review, H2 2013, New Report Launched

Rheumatoid Arthritis - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Rheumatoid Arthritis - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
• A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 392 pages, 277 tables and 14 figures, “Rheumatoid Arthritis - Pipeline Review, H2 2013” report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Rheumatoid Arthritis Overview, Rheumatoid Arthritis Therapeutics under Development by Companies, Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes, Drug Profiles, Rheumatoid Arthritis Therapeutics - Drug Profile Updates, Rheumatoid Arthritis Therapeutics - Discontinued Products, Rheumatoid Arthritis Therapeutics - Dormant Products, Rheumatoid Arthritis - Product Development Milestones.  The report covers 201 companies; few are Alcon, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., Amgen Inc., Antares Pharma, Inc., AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Inovio Biomedical Corporation. Find all: Healthcare Market Research Reports